EGFR and colorectal carcinoma: In anti-EGFR targeted therapy, patients with high c-MYC expression had a markedly lower PFS, OS and more frequent metastases compared to patients with low c-MYC expression, which suggests a pivotal role of c-MYC in CRC resistance to EGFR inhibitors (75).